Glargine did not reduce CV events more than standard care in patients with dysglycemia
Authors: Ellis Lader
Journal: Annals of Internal Medicine (2012)

ACP Journal Club18 September 2012Glargine did not reduce CV events more than standard care in patients with dysglycemiaEllis Lader, MDEllis Lader, MDMid Valley Cardiology, New York University School of Medicine, Kingston, New York, USA (E.L.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-157-6-201209180-02010 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319-28. https://pubmed.ncbi.nlm.nih.gov/22686416Clinical Impact RatingsGIM/FP/GP: Cardiology: Endocrinology: References1 Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86. [PMID: 8366922] Google Scholar2 Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59. [PMID: 18539917] Google Scholar3 ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-72. [PMID: 18539916] Google Scholar4 Duckworth W, Abraira C, Moritz T, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-39. [PMID: 19092145] Google Scholar5 Sobel BE, Hardison RM, Genuth S, et al; BARI 2D Investigators. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 2011;124:695-703. [PMID: 21768545] Google Scholar6 Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. [PMID: 11832527] Google Scholar7 Daviglus ML, Stamler J, Orencia AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med. 1997;336:1046-53. [PMID: 9091800] Google Scholar Author, Article, and Disclosure InformationAuthors: Ellis Lader, MDAffiliations: Mid Valley Cardiology, New York University School of Medicine, Kingston, New York, USA (E.L.)This article was published at Annals.org on 4 September 2012. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoDaily n-3 fatty acid supplements did not reduce CV events in high-risk patients with dysglycemia Ellis Lader Metrics 18 September 2012Volume 157, Issue 6Page: JC3-10KeywordsFatty acidsGlucoseHeart failureHypoglycemiaInsulinMortalityMyocardial infarctionOilsRevascularizationType 2 diabetes ePublished: 18 September 2012 Issue Published: 18 September 2012 Copyright & PermissionsCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...